Skip to main content

Table 2 Treatment-emergent adverse events of any grade and grade ≥ 3

From: Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients

Event

All Grade

Grade ≥ 3

Alanine aminotransferase increased

13 (26.5%)

0

Aspartate aminotransferase increased

11 (22.4%)

0

Blood bilirubin increased

4 (8.2%)

0

Blood creatine phosphokinase increased

14 (28.6%)

3(6.1%)

White blood cell count decreased

9 (18.4%)

0

Neutrophil count decreased

5 (10.2%)

0

Platelet count decreased

15 (30.6%)

0

Rash

10 (20.4%)

0

Pruritus

4 (8.2%)

0

Diarrhea

6 (12.2%)

0